Anixa Biosciences (NASDAQ:ANIX) Lowered to Sell Rating by Wall Street Zen

Anixa Biosciences (NASDAQ:ANIX) was downgraded by investment analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Saturday.

A number of other brokerages have also recently issued reports on ANIX. Weiss Ratings reissued a “sell (d-)” rating on shares of Anixa Biosciences in a report on Monday, December 29th. Zacks Research lowered Anixa Biosciences from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, November 18th. Finally, D. Boral Capital reiterated a “buy” rating and issued a $10.00 price target on shares of Anixa Biosciences in a research report on Wednesday. Three equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Anixa Biosciences presently has a consensus rating of “Hold” and an average price target of $9.00.

Anixa Biosciences Stock Performance

Shares of ANIX stock opened at $2.96 on Friday. The firm has a fifty day moving average of $3.48 and a 200-day moving average of $3.58. The stock has a market cap of $98.80 million, a price-to-earnings ratio of -8.46 and a beta of 0.53. Anixa Biosciences has a 52-week low of $2.33 and a 52-week high of $5.46.

Anixa Biosciences (NASDAQ:ANIX) last posted its earnings results on Monday, January 12th. The company reported ($0.09) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.09). On average, sell-side analysts predict that Anixa Biosciences will post -0.41 earnings per share for the current year.

Insider Buying and Selling

In other Anixa Biosciences news, Director Arnold M. Baskies purchased 10,000 shares of the company’s stock in a transaction that occurred on Wednesday, January 28th. The stock was purchased at an average cost of $3.04 per share, with a total value of $30,400.00. Following the acquisition, the director directly owned 135,000 shares of the company’s stock, valued at approximately $410,400. This trade represents a 8.00% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this link. 26.40% of the stock is currently owned by company insiders.

Institutional Trading of Anixa Biosciences

Several large investors have recently made changes to their positions in ANIX. Susquehanna International Group LLP grew its holdings in Anixa Biosciences by 378.4% during the 3rd quarter. Susquehanna International Group LLP now owns 80,387 shares of the company’s stock worth $265,000 after acquiring an additional 63,584 shares during the last quarter. Prosperity Wealth Management Inc. raised its stake in shares of Anixa Biosciences by 14.5% in the third quarter. Prosperity Wealth Management Inc. now owns 41,800 shares of the company’s stock worth $138,000 after acquiring an additional 5,300 shares during the last quarter. Citadel Advisors LLC increased its holdings in shares of Anixa Biosciences by 31.6% in the third quarter. Citadel Advisors LLC now owns 96,010 shares of the company’s stock valued at $317,000 after purchasing an additional 23,072 shares in the last quarter. Bank of America Corp DE raised its position in Anixa Biosciences by 1.7% in the 3rd quarter. Bank of America Corp DE now owns 213,955 shares of the company’s stock worth $706,000 after purchasing an additional 3,645 shares during the last quarter. Finally, Vanguard Group Inc. raised its position in Anixa Biosciences by 2.1% in the 3rd quarter. Vanguard Group Inc. now owns 1,422,342 shares of the company’s stock worth $4,694,000 after purchasing an additional 29,436 shares during the last quarter. Institutional investors own 29.13% of the company’s stock.

Anixa Biosciences Company Profile

Anixa Biosciences is a clinical-stage immuno-oncology and infectious disease company developing novel cell-based immunotherapies and vaccine platforms. Through its Anixa Therapeutics division, the company is advancing antibody and T-cell modalities, including an ovarian cancer immunotherapy candidate and a COVID-19 vaccine leveraging a proprietary virus-like particle (VLP) technology. Its research pipeline emphasizes modular vaccine design and personalized cancer cell therapy aimed at inducing durable immune responses against solid tumors.

In parallel, Anixa Diagnostics is developing the ADAPT diagnostic platform, a high-throughput proteomics approach using engineered peptides derived from spider venom.